Altus secures Althea as phase 3 manufacturer for growth hormone ALTU-238

By E. Janene Geiss

Philadelphia, Aug. 22 - Altus Pharmaceuticals Inc. said it has signed an agreement with Althea Technologies, Inc. a contract manufacturing organization, to manufacture human growth hormone ALTU-238 for use in the planned phase 3 clinical trials of the drug candidate.

ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone that employs Altus' proprietary protein crystallization and formulation technology, according to a company news release.

"Althea Technologies is a seasoned CMO with significant experience in the manufacture of recombinant proteins," Sheldon Berkle, president and chief executive officer of Altus, said in the release.

Althea is a San Diego pharmaceutical services firm.

Altus is a Cambridge, Mass., biopharmaceutical company focused on oral and injectable protein therapeutics for gastrointestinal and metabolic disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.